Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.

This year's JPMorgan health-care conference took place a month after UnitedHealthcare CEO Brian Thompson was fatally shot in ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

The team categorized pediatric obesity treatment response, based on changes in body mass index standard deviation score, as ...

Butler University's plans to renovate and expand Clowes Memorial Hall, including the addition of a ballroom space, aim to ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

Eli Lilly recently updated Q4 revenue guidance, and sales are expected to come in lower than previously anticipated. While this could suggest the company is experiencing sluggish or plateauing ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...